Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Requirement of FAT and DCHS protocadherins during hypothalamic-pituitary development
Emily J. Lodge, … , Constantine A. Stratakis, Cynthia L. Andoniadou
Emily J. Lodge, … , Constantine A. Stratakis, Cynthia L. Andoniadou
Published October 27, 2020
Citation Information: JCI Insight. 2020;5(23):e134310. https://doi.org/10.1172/jci.insight.134310.
View: Text | PDF
Research Article Development Endocrinology

Requirement of FAT and DCHS protocadherins during hypothalamic-pituitary development

  • Text
  • PDF
Abstract

Pituitary developmental defects lead to partial or complete hormone deficiency and significant health problems. The majority of cases are sporadic and of unknown cause. We screened 28 patients with pituitary stalk interruption syndrome for mutations in the FAT/DCHS family of protocadherins that have high functional redundancy. We identified 7 variants, 4 of which are putatively damaging, in FAT2 and DCHS2 in 6 patients with pituitary developmental defects recruited through a cohort of patients with mostly ectopic posterior pituitary gland and/or pituitary stalk interruption. All patients had growth hormone deficiency, and 2 presented with multiple hormone deficiencies and small glands. FAT2 and DCHS2 were strongly expressed in the mesenchyme surrounding the normal developing human pituitary. We analyzed Dchs2–/– mouse mutants and identified anterior pituitary hypoplasia and partially penetrant infundibular defects. Overlapping infundibular abnormalities and distinct anterior pituitary morphogenesis defects were observed in Fat4–/– and Dchs1–/– mouse mutants, but all animal models displayed normal commitment to anterior pituitary cell types. Together our data implicate FAT/DCHS protocadherins in normal hypothalamic-pituitary development and identify FAT2 and DCHS2 as candidates underlying pituitary gland developmental defects such as ectopic pituitary gland and/or pituitary stalk interruption.

Authors

Emily J. Lodge, Paraskevi Xekouki, Tatiane S. Silva, Cristiane Kochi, Carlos A. Longui, Fabio R. Faucz, Alice Santambrogio, James L. Mills, Nathan Pankratz, John Lane, Dominika Sosnowska, Tina Hodgson, Amanda L. Patist, Philippa Francis-West, Françoise Helmbacher, Constantine A. Stratakis, Cynthia L. Andoniadou

×

Figure 4

FAT4 and DCHS1 are required for normal murine pituitary development.

Options: View larger image (or click on image) Download as PowerPoint
FAT4 and DCHS1 are required for normal murine pituitary development.
(A)...
(A) RNAscope mRNA in situ hybridization on sagittal sections through WT murine pituitaries at 18.5 dpc using probes against Fat4 and Dchs1 (n = 3). Abundant Fat4 transcripts are detected in the pars tuberalis, infundibulum, developing pituitary stalk, and mesenchyme surrounding definitive RP. Some transcripts are also detected in RP. Expression of Dchs1 is detected at low levels throughout these tissues. (B) Hematoxylin and eosin staining of sagittal sections through Dchs1–/– (n = 5), Fat4–/– (n = 10), and control pituitaries (n = 15) at 13.0 dpc showing invaginations in the infundibulum of Fat4–/– mutants (arrowheads), not observed in control or Dchs1–/– embryos. RNAscope mRNA in situ hybridization on sagittal sections through control WT and Fat4–/– pituitaries at 13.5 dpc using specific probes against Fat3 marking the ventral diencephalon and infundibulum, which is abnormal in mutants (arrowheads). (C) Wholemount images taken at dorsal (top panels) and frontal views (bottom panels) of control, Dchs1–/– (n = 10), and Fat4–/– (n = 8) pituitaries at P0. Both Dchs1–/– and Fat4–/– mutants have a shortened medio-lateral axis affecting the anterior lobe compared with control. (D) Immunofluorescence staining on Fat4–/– pituitaries and littermate controls at 18.5 dpc using antibodies against lineage-committed progenitor markers PIT1, TPIT, and SF1 and hormones TSH, GH, and ACTH (n = 3). Staining is comparable for all markers between genotypes. Inf, infundibulum; PS, pituitary stalk; PT, pars tuberalis; M, mesenchyme; VD, ventral diencephalon; PL, posterior lobe; IL, intermediate lobe; AL, anterior lobe. Scale bars: 250 μm (A and B), 100 μm (D). For insets in A, original magnification, ×2.7.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts